Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Pass Above Two Hundred Day Moving Average – Here’s Why

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $48.87 and traded as high as $59.96. Global X Genomics & Biotechnology ETF shares last traded at $59.72, with a volume of 15,583 shares traded.

Global X Genomics & Biotechnology ETF Price Performance

The company has a market capitalization of $86.39 million, a price-to-earnings ratio of -25.29 and a beta of 1.17. The business has a fifty day moving average price of $54.50 and a 200 day moving average price of $48.93.

Global X Genomics & Biotechnology ETF Announces Dividend

The business also recently announced a dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 29th were given a $0.0579 dividend. The ex-dividend date was Monday, June 29th. Global X Genomics & Biotechnology ETF’s dividend payout ratio is currently -27.35%.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Large investors have recently bought and sold shares of the stock. U.S. Capital Wealth Advisors LLC bought a new position in shares of Global X Genomics & Biotechnology ETF in the fourth quarter valued at approximately $575,000. Sei Investments Co. increased its stake in shares of Global X Genomics & Biotechnology ETF by 110.4% during the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after acquiring an additional 12,105 shares during the period. Jane Street Group LLC raised its holdings in Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after purchasing an additional 10,308 shares in the last quarter. C M Bidwell & Associates Ltd. acquired a new stake in Global X Genomics & Biotechnology ETF in the second quarter worth approximately $242,000. Finally, Bank of America Corp DE lifted its position in Global X Genomics & Biotechnology ETF by 67.8% in the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after purchasing an additional 48,394 shares during the period. Institutional investors and hedge funds own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.